SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Y-mAbs Therapeutics, Inc. – ‘10-Q’ for 9/30/21 – ‘EX-101.CAL’

On:  Thursday, 11/4/21, at 3:14pm ET   ·   For:  9/30/21   ·   Accession #:  1558370-21-14548   ·   File #:  1-38650

Previous ‘10-Q’:  ‘10-Q’ on 8/9/21 for 6/30/21   ·   Next:  ‘10-Q’ on 5/9/22 for 3/31/22   ·   Latest:  ‘10-Q’ on 11/13/23 for 9/30/23   ·   4 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/04/21  Y-mAbs Therapeutics, Inc.         10-Q        9/30/21   76:7.4M                                   Toppan Merrill Bridge/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.27M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     23K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     23K 
12: R1          Document and Entity Information                     HTML     75K 
13: R2          Consolidated Balance Sheets                         HTML    116K 
14: R3          Consolidated Balance Sheets (Parenthetical)         HTML     34K 
15: R4          Consolidated Statements of Net Loss and             HTML     92K 
                Comprehensive Loss                                               
16: R5          Consolidated Statements of Changes in               HTML     95K 
                Stockholders' Equity                                             
17: R6          Consolidated Statements of Cash Flows               HTML     98K 
18: R7          Organization and Description of Business            HTML     24K 
19: R8          Basis of Presentation                               HTML     29K 
20: R9          Summary of Significant Accounting Policies          HTML     78K 
21: R10         Product Revenue                                     HTML     58K 
22: R11         Net Loss Per Share                                  HTML     48K 
23: R12         Inventory                                           HTML     38K 
24: R13         Accrued Liabilities                                 HTML     42K 
25: R14         License Agreements and Commitments                  HTML    150K 
26: R15         Stockholders' Equity                                HTML     33K 
27: R16         Share-Based Compensation                            HTML     92K 
28: R17         Related Party Transactions                          HTML     25K 
29: R18         Income Taxes                                        HTML     27K 
30: R19         Other Benefits                                      HTML     24K 
31: R20         Gain From Sale of Priority Review Voucher           HTML     24K 
32: R21         Summary of Significant Accounting Policies          HTML    104K 
                (Policies)                                                       
33: R22         Summary of Significant Accounting Policies          HTML     59K 
                (Tables)                                                         
34: R23         Product Revenue (Tables)                            HTML     52K 
35: R24         Net Loss Per Share (Tables)                         HTML     47K 
36: R25         Inventory (Tables)                                  HTML     39K 
37: R26         Accrued Liabilities (Tables)                        HTML     41K 
38: R27         License Agreements and Commitments (Tables)         HTML    141K 
39: R28         Share-Based Compensation (Tables)                   HTML     84K 
40: R29         BASIS OF PRESENTATION - Accumulated deficit         HTML     25K 
                (Details)                                                        
41: R30         BASIS OF PRESENTATION - Secondary public offering   HTML     34K 
                (Details)                                                        
42: R31         BASIS OF PRESENTATION - Cash and cash equivalents   HTML     24K 
                (Details)                                                        
43: R32         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     29K 
                Concentration of Credit Risk (Details)                           
44: R33         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair   HTML     40K 
                Value Measurement (Details)                                      
45: R34         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     49K 
                Revenue Recognition - License Revenue (Details)                  
46: R35         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     23K 
                Segment (Details)                                                
47: R36         PRODUCT REVENUE - Discounts and Allowances          HTML     59K 
                (Details)                                                        
48: R37         PRODUCT REVENUE - Concentrations (Details)          HTML     33K 
49: R38         NET LOSS PER SHARE - Basic and diluted (Details)    HTML     49K 
50: R39         NET LOSS PER SHARE - Anti-dilutive securities       HTML     23K 
                (Details)                                                        
51: R40         Inventory (Details)                                 HTML     28K 
52: R41         Accrued Liabilities (Details)                       HTML     36K 
53: R42         LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and  HTML     66K 
                MabVax License Agreement (Details)                               
54: R43         LICENSE AGREEMENTS AND COMMITMENTS - Other          HTML     40K 
                agreements (Details)                                             
55: R44         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     64K 
                agreements (Details)                                             
56: R45         LICENSE AGREEMENTS AND COMMITMENTS - Lease costs    HTML     31K 
                (Details)                                                        
57: R46         LICENSE AGREEMENTS AND COMMITMENTS - Lease          HTML     38K 
                maturities (Details)                                             
58: R47         LICENSE AGREEMENTS AND COMMITMENTS - Lease term     HTML     26K 
                and discount rate (Details)                                      
59: R48         STOCKHOLDERS' EQUITY - Authorized, Common and       HTML     40K 
                Preferred Stock (Details)                                        
60: R49         STOCKHOLDERS' EQUITY - Stock grant agreements with  HTML     77K 
                non-employees (Details)                                          
61: R50         STOCKHOLDERS' EQUITY - Issuance of common stock     HTML     38K 
                (Details)                                                        
62: R51         SHARE-BASED COMPENSATION - 2015 Plan (Details)      HTML     31K 
63: R52         SHARE-BASED COMPENSATION - 2018 Plan (Details)      HTML     41K 
64: R53         SHARE-BASED COMPENSATION - Stock option expense     HTML     34K 
                (Details)                                                        
65: R54         SHARE-BASED COMPENSATION - Stock option activity    HTML     64K 
                (Details)                                                        
66: R55         SHARE-BASED COMPENSATION - Stock option             HTML     28K 
                unrecognized compensation (Details)                              
67: R56         SHARE-BASED COMPENSATION - Restricted Stock Unit    HTML     62K 
                Activity (Details)                                               
68: R57         Related Party Transactions (Details)                HTML     39K 
69: R58         INCOME TAXES - Expense (Details)                    HTML     35K 
70: R59         INCOME TAXES - Uncertain tax positions (Details)    HTML     23K 
71: R60         Other Benefits (Details)                            HTML     29K 
72: R61         Gain From Sale of Priority Review Voucher           HTML     34K 
                (Details)                                                        
74: XML         IDEA XML File -- Filing Summary                      XML    135K 
11: XML         XBRL Instance -- ymab-20210930x10q_htm               XML   1.65M 
73: EXCEL       IDEA Workbook of Financial Reports                  XLSX     86K 
 7: EX-101.CAL  XBRL Calculations -- ymab-20210930_cal               XML    132K 
 8: EX-101.DEF  XBRL Definitions -- ymab-20210930_def                XML    529K 
 9: EX-101.LAB  XBRL Labels -- ymab-20210930_lab                     XML   1.10M 
10: EX-101.PRE  XBRL Presentations -- ymab-20210930_pre              XML    841K 
 6: EX-101.SCH  XBRL Schema -- ymab-20210930                         XSD    161K 
75: JSON        XBRL Instance as JSON Data -- MetaLinks              340±   491K 
76: ZIP         XBRL Zipped Folder -- 0001558370-21-014548-xbrl      Zip    302K

‘EX-101.CAL’   —   XBRL Calculations — ymab-20210930_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Toppan Merrill Bridge 9.6.7908.23199 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 11/4/2021 7:05:15 PM -->
<!-- Modified on: 11/4/2021 7:05:15 PM -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.ymabs.com/role/StatementConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.ymabs.com/role/StatementConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#DisclosureProductRevenueDiscountsAndAllowancesDetails" roleURI="http://www.ymabs.com/role/DisclosureProductRevenueDiscountsAndAllowancesDetails"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#DisclosureInventoryDetails" roleURI="http://www.ymabs.com/role/DisclosureInventoryDetails"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetailsCalc2" roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetailsCalc2"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://www.ymabs.com/role/DisclosureAccruedLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetails" roleURI="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="ymab-20210930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.ymabs.com/role/DisclosureRelatedPartyTransactionsDetails"/>
<calculationLink xlink:role="http://www.ymabs.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637716495140525806" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637716495140525806" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637716495140525806" order="1" use="optional" weight="1" priority="4"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637716495140525806" xlink:to="us-gaap_AccountsReceivableNetCurrent_637716495140525806" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637716495140525806" xlink:to="us-gaap_InventoryNet_637716495140525806" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637716495140525806" xlink:to="us-gaap_OtherAssetsCurrent_637716495140525806" order="4" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637716495140525806" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637716495140525806" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637716495140525806"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637716495140525806" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637716495140535619"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637716495140535619" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637716495140535619"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637716495140535619" xlink:to="us-gaap_LiabilitiesCurrent_637716495140535619" order="1" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637716495140535619"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637716495140535619" xlink:to="us-gaap_AccountsPayableCurrent_637716495140535619" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637716495140535619"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637716495140535619" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637716495140535619" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637716495140535619"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637716495140535619" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637716495140535619" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_AccruedMilestoneAndRoyaltyPaymentsNoncurrent" xlink:label="ymab_AccruedMilestoneAndRoyaltyPaymentsNoncurrent_637716495140535619"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637716495140535619" xlink:to="ymab_AccruedMilestoneAndRoyaltyPaymentsNoncurrent_637716495140535619" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637716495140535619"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637716495140535619" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637716495140535619" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637716495140545601"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637716495140535619" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637716495140545601" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637716495140545601"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637716495140545601" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637716495140545601"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637716495140545601" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637716495140545601"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637716495140545601" xlink:to="us-gaap_PreferredStockValue_637716495140545601" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637716495140545601"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637716495140545601" xlink:to="us-gaap_CommonStockValue_637716495140545601" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637716495140545601"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637716495140545601" xlink:to="us-gaap_AdditionalPaidInCapital_637716495140545601" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637716495140545601"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637716495140545601" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637716495140545601" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637716495140555575"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637716495140545601" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637716495140555575" order="5" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637716495140555575"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637716495140555575" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637716495140555575"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637716495140555575" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_637716495140555575"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637716495140555575" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_637716495140555575" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637716495140555575"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637716495140555575" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637716495140555575" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637716495140555575"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637716495140555575" xlink:to="us-gaap_OperatingIncomeLoss_637716495140555575" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637716495140555575"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637716495140555575" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637716495140555575" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637716495140565547"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637716495140555575" xlink:to="us-gaap_CostsAndExpenses_637716495140565547" order="2" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_637716495140565547"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637716495140565547" xlink:to="us-gaap_CostOfGoodsAndServicesSold_637716495140565547" order="1" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637716495140565547"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637716495140565547" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637716495140565547" order="2" use="optional" weight="1" priority="4"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold" xlink:label="ymab_RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold_637716495140565547"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637716495140565547" xlink:to="ymab_RoyaltyExpenseExcludingCostsIncludedInCostOfGoodsAndServicesSold_637716495140565547" order="3" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637716495140565547"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_637716495140565547" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637716495140565547" order="4" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" order="1" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637716495140565547"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_ProfitLoss_637716495140565547" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_637716495140575616" order="2" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637716495140575616" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_ShareBasedCompensation_637716495140575616" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_NoncashStockIssuanceCostsToStrategicPartner" xlink:label="ymab_NoncashStockIssuanceCostsToStrategicPartner_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="ymab_NoncashStockIssuanceCostsToStrategicPartner_637716495140575616" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637716495140575616" order="6" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637716495140575616" order="7" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637716495140575616" order="8" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637716495140575616"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_IncreaseDecreaseInInventories_637716495140575616" order="9" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_637716495140585709"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_637716495140585709" order="10" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637716495140585709"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637716495140585709" order="11" use="optional" weight="-1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637716495140585709"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637716495140585709" order="12" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_IncreaseDecreaseInAccruedLiabilitiesAndOther" xlink:label="ymab_IncreaseDecreaseInAccruedLiabilitiesAndOther_637716495140585709"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637716495140565547" xlink:to="ymab_IncreaseDecreaseInAccruedLiabilitiesAndOther_637716495140585709" order="13" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637716495140585709"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637716495140585709" order="2" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637716495140585709"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637716495140585709" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637716495140585709" order="1" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_637716495140585709"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637716495140585709" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_637716495140585709" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_637716495140595553"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637716495140585709" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_637716495140595553" order="3" use="optional" weight="-1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637716495140595553"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637716495140595553" order="3" use="optional" weight="1" priority="3"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637716495140595553"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637716495140595553" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637716495140595553" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637716495140595553"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637716495140595553" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637716495140595553" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637716495140595553"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637716495140595553" order="4" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/DisclosureProductRevenueDiscountsAndAllowancesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PRODUCT REVENUE - Discounts and Allowances (Details)">
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ReservesAndAllowancesAdditions" xlink:label="ymab_ReservesAndAllowancesAdditions"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ReserveForDiscountsAdditions" xlink:label="ymab_ReserveForDiscountsAdditions_637716495140595553"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesAdditions" xlink:to="ymab_ReserveForDiscountsAdditions_637716495140595553" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ContractualAllowanceAndGovernmentRebateLiabilityAdditions" xlink:label="ymab_ContractualAllowanceAndGovernmentRebateLiabilityAdditions_637716495140605577"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesAdditions" xlink:to="ymab_ContractualAllowanceAndGovernmentRebateLiabilityAdditions_637716495140605577" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_SalesReturnLiabilityAdditions" xlink:label="ymab_SalesReturnLiabilityAdditions_637716495140605577"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesAdditions" xlink:to="ymab_SalesReturnLiabilityAdditions_637716495140605577" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ReservesAndAllowancesBalance" xlink:label="ymab_ReservesAndAllowancesBalance"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ReserveForDiscountsBalance" xlink:label="ymab_ReserveForDiscountsBalance_637716495140605577"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesBalance" xlink:to="ymab_ReserveForDiscountsBalance_637716495140605577" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ContractualAllowanceAndGovernmentRebateLiabilityBalance" xlink:label="ymab_ContractualAllowanceAndGovernmentRebateLiabilityBalance_637716495140605577"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesBalance" xlink:to="ymab_ContractualAllowanceAndGovernmentRebateLiabilityBalance_637716495140605577" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ReservesAndAllowancesReductions" xlink:label="ymab_ReservesAndAllowancesReductions"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ReserveForDiscountsReduction" xlink:label="ymab_ReserveForDiscountsReduction_637716495140605577"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesReductions" xlink:to="ymab_ReserveForDiscountsReduction_637716495140605577" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_ContractualAllowanceAndGovernmentRebateLiabilityReduction" xlink:label="ymab_ContractualAllowanceAndGovernmentRebateLiabilityReduction_637716495140765609"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesReductions" xlink:to="ymab_ContractualAllowanceAndGovernmentRebateLiabilityReduction_637716495140765609" order="2" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_SalesReturnLiabilityReduction" xlink:label="ymab_SalesReturnLiabilityReduction_637716495140765609"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ymab_ReservesAndAllowancesReductions" xlink:to="ymab_SalesReturnLiabilityReduction_637716495140765609" order="3" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="40601 - Disclosure - INVENTORY (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637716495140765609"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637716495140765609" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637716495140765609"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637716495140765609" order="2" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetailsCalc2" xlink:type="extended" xlink:title="40608 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease maturities (Details) (calc 2)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637716495140765609"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637716495140765609" order="1" use="optional" weight="1" priority="1"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637716495140775727"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637716495140775727" order="2" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - ACCRUED LIABILITIES (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent" xlink:label="ymab_AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent_637716495140775727"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ymab_AccruedLicensingMilestoneAndRoyaltyPaymentsCurrent_637716495140775727" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_AccruedClinicalCostsCurrent" xlink:label="ymab_AccruedClinicalCostsCurrent_637716495140775727"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ymab_AccruedClinicalCostsCurrent_637716495140775727" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_AccruedCompensationAndBoardFeesCurrent" xlink:label="ymab_AccruedCompensationAndBoardFeesCurrent_637716495140775727"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ymab_AccruedCompensationAndBoardFeesCurrent_637716495140775727" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_AccruedManufacturingCostsCurrent" xlink:label="ymab_AccruedManufacturingCostsCurrent_637716495140775727"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ymab_AccruedManufacturingCostsCurrent_637716495140775727" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="ymab-20210930.xsd#ymab_AccruedSalesReservesCurrent" xlink:label="ymab_AccruedSalesReservesCurrent_637716495140775727"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ymab_AccruedSalesReservesCurrent_637716495140775727" order="5" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637716495140785793"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637716495140785793" order="6" use="optional" weight="1" priority="3"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/DisclosureLicenseAgreementsAndCommitmentsLeaseMaturitiesDetails" xlink:type="extended" xlink:title="40805 - Disclosure - LICENSE AGREEMENTS AND COMMITMENTS - Lease maturities (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637716495140785793"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637716495140785793" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637716495140785793"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637716495140785793" order="2" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637716495140785793"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637716495140785793" order="3" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637716495140785793"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637716495140785793" order="4" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637716495140785793"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637716495140785793" order="5" use="optional" weight="1" priority="2"/>
</calculationLink>
<calculationLink xlink:role="http://www.ymabs.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_637716495140795559"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_637716495140795559" order="1" use="optional" weight="1" priority="2"/>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_637716495140795559"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_637716495140795559" order="2" use="optional" weight="1" priority="2"/>
</calculationLink>
</link:linkbase>

4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/06/21  Y-mAbs Therapeutics, Inc.         10-Q        3/31/21   76:6.3M                                   Toppan Merrill Bridge/FA
11/05/20  Y-mAbs Therapeutics, Inc.         10-Q        9/30/20   68:6.7M                                   Toppan Merrill Bridge/FA
 9/26/18  Y-mAbs Therapeutics, Inc.         8-K:5,7,9   9/25/18    4:284K                                   Toppan Merrill/FA
 8/24/18  Y-mAbs Therapeutics, Inc.         S-1                   31:12M                                    Toppan Merrill-FA
↑Top
Filing Submission 0001558370-21-014548   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 1, 1:28:26.1am ET